Theravance Biopharma, Inc. - Common Stock (TBPH)

Historical Holders from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
TBPH on Nasdaq
Shares outstanding
49,779,938
Price per share
$18.71
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
48,375,341
Total reported value
$706,279,610
% of total 13F portfolios
0%
Share change
+2,403,198
Value change
+$36,991,565
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
158
Price from insider filings
$18.75
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Theravance Biopharma, Inc. - Common Stock (TBPH) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Newtyn Management, LLC 9.7% $46,384,679 4,757,403 Newtyn Management, LLC 31 Dec 2024
BlackRock, Inc. 6.5% $31,548,036 3,235,696 BlackRock, Inc. 31 Mar 2025
As of 30 Sep 2025, Theravance Biopharma, Inc. - Common Stock (TBPH) has 158 institutional shareholders filing 13F forms. They hold 48,375,341 shares. of 49,779,938 outstanding shares (97%) .

Top 25 institutional shareholders own 87% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
Madison Avenue Partners, LP 19% 9,511,150 0% 8.3% $138,862,790
Weiss Asset Management LP 15% 7,457,060 0% 1.7% $108,873,076
Newtyn Management, LLC 9.9% 4,950,000 0% 8.8% $72,270,000
BlackRock, Inc. 8.2% 4,068,994 -1.7% 0% $59,407,312
Irenic Capital Management LP 5.5% 2,760,948 0% 7.9% $40,309,841
VANGUARD GROUP INC 4.4% 2,211,582 +2.5% 0% $32,289,097
Park West Asset Management LLC 2.6% 1,284,081 -29% 1.7% $18,747,583
D. E. Shaw & Co., Inc. 2.4% 1,209,312 +21% 0.01% $17,655,955
Oasis Management Co Ltd. 2.2% 1,118,935 0% 2.8% $16,336,451
ACADIAN ASSET MANAGEMENT LLC 2.2% 1,089,381 +253% 0.03% $15,899,000
STATE STREET CORP 2.1% 1,055,905 +2% 0% $15,416,213
GEODE CAPITAL MANAGEMENT, LLC 1.8% 897,990 +0.45% 0% $13,113,478
DIMENSIONAL FUND ADVISORS LP 1.5% 766,704 +6.2% 0% $11,193,148
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 1.5% 726,783 0.01% $10,611,032
MORGAN STANLEY 1.2% 599,551 +8.9% 0% $8,753,444
BANK OF AMERICA CORP /DE/ 1.1% 527,107 -2.3% 0% $7,695,763
UBS Group AG 1% 514,170 +29% 0% $7,506,883
Assenagon Asset Management S.A. 0.83% 414,715 +1629% 0.01% $6,054,839
BNP PARIBAS FINANCIAL MARKETS 0.75% 373,600 0% 0% $5,454,560
MARSHALL WACE, LLP 0.72% 357,651 +255% 0.01% $5,221,705
NORTHERN TRUST CORP 0.69% 341,306 -3.1% 0% $4,983,068
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.64% 320,144 +5.3% 0% $4,674,102
Hillsdale Investment Management Inc. 0.62% 310,700 0.14% $4,536,220
TANG CAPITAL MANAGEMENT LLC 0.53% 264,308 0% 0.15% $3,858,897
GOLDMAN SACHS GROUP INC 0.52% 258,648 +30% 0% $3,776,261

Institutional Holders of Theravance Biopharma, Inc. - Common Stock (TBPH) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 419,879 $7,855,474 -$52,516 1,871.06% 6
2025 Q3 48,375,341 $706,279,610 +$36,991,565 1,460% 158
2025 Q2 46,436,015 $512,193,131 +$17,041,767 1,103% 134
2025 Q1 44,895,013 $400,910,124 +$805,783 893% 130
2024 Q4 44,887,720 $422,397,233 -$6,899,094 941% 128
2024 Q3 45,764,660 $368,891,703 -$13,728,533 806% 118
2024 Q2 47,101,751 $399,477,630 -$8,156,185 848% 129
2024 Q1 47,958,440 $430,313,409 -$10,017,643 897% 119
2023 Q4 48,815,898 $548,690,907 -$21,251,604 1,124% 116
2023 Q3 50,811,645 $438,505,371 -$20,825,244 863% 113
2023 Q2 52,784,275 $546,345,758 -$76,354,796 1,035% 117
2023 Q1 60,151,070 $652,600,279 -$20,647,357 1,085% 112
2022 Q4 62,093,388 $696,433,955 -$41,903,451 1,122% 118
2022 Q3 64,074,481 $649,741,089 +$1,849,322 1,014% 114
2022 Q2 64,209,180 $581,714,921 +$11,702,533 906% 106
2022 Q1 62,986,284 $602,166,380 +$31,622,746 955.99% 114
2021 Q4 59,337,727 $655,471,603 -$7,845,717 1,104.98% 109
2021 Q3 60,653,808 $448,777,384 -$37,107,153 740% 111
2021 Q2 60,758,215 $882,854,201 +$106,504,226 1,452% 101
2021 Q1 53,537,579 $1,092,709,410 +$7,301,237 2,041% 104
2020 Q4 53,239,274 $946,045,510 +$17,733,590 1,777% 103
2020 Q3 52,459,569 $775,625,748 -$4,497,125 1,478.48% 113
2020 Q2 52,961,450 $1,111,646,885 -$95,003,651 2,099% 121
2020 Q1 56,904,286 $1,315,179,943 +$267,872,903 2,311% 102
2019 Q4 44,821,941 $1,159,982,320 -$103,049,474 2,588.98% 103
2019 Q3 46,191,630 $899,811,276 -$42,270,083 1,948% 87
2019 Q2 48,624,391 $794,038,148 +$6,064,175 1,633% 94
2019 Q1 48,467,789 $1,098,829,213 +$14,666,557 2,267.02% 98
2018 Q4 47,693,431 $1,220,447,234 -$168,216 2,558.99% 92
2018 Q3 47,402,456 $1,548,591,468 +$9,259,415 3,267% 90
2018 Q2 47,820,954 $1,084,574,647 +$2,240,117 2,267.99% 83
2018 Q1 47,702,533 $1,156,766,841 +$19,411,519 2,425% 85
2017 Q4 46,927,458 $1,308,786,945 -$13,545,795 2,789% 79
2017 Q3 47,312,839 $1,619,998,372 +$33,457,548 3,424% 80
2017 Q2 46,303,381 $1,844,748,924 +$47,996,533 3,983.98% 91
2017 Q1 45,113,403 $1,660,949,113 +$168,197,871 3,682% 90
2016 Q4 43,817,541 $1,396,888,696 +$262,074,543 3,188% 96
2016 Q3 35,300,039 $1,277,832,411 +$76,633,705 3,623.98% 98
2016 Q2 33,917,613 $769,608,364 +$131,840,765 2,269.02% 94
2016 Q1 28,150,667 $529,049,830 +$42,674,071 1,880.01% 77
2015 Q4 25,928,974 $424,968,625 +$85,947,257 1,639% 79
2015 Q3 20,539,324 $225,719,337 -$24,553,140 1,099.02% 78
2015 Q2 22,422,337 $291,927,279 +$16,321,496 1,301.98% 84
2015 Q1 20,888,616 $362,467,742 +$7,467,773 1,734.94% 84
2014 Q4 20,412,218 $304,588,647 -$33,281,851 1,492% 86
2014 Q3 21,271,423 $490,440,514 +$17,057,826 2,305% 86
2014 Q2 20,300,819 $647,804,482 +$647,740,494 3,188.04% 89
2014 Q1 842 $14,609 1,735.04% 1